Morpholine → HCID 59592972, compound

HRID 2262156Notes

Reaction equation

HRID 2262156 reaction equation
[NH:1]1[C:9]2[C:4](=[C:5]([C:10]3[N:11]=[C:12]([N:22]4[CH2:27][CH2:26][O:25][CH2:24][CH2:23]4)[C:13]4[S:18][C:17]([C:19]([OH:21])=O)=[CH:16][C:14]=4[N:15]=3)[CH:6]=[CH:7][CH:8]=2)[CH:3]=[N:2]1.[NH:28]1[CH2:33][CH2:32][O:31][CH2:30][CH2:29]1>>[NH:1]1[C:9]2[C:4](=[C:5]([C:10]3[N:11]=[C:12]([N:22]4[CH2:27][CH2:26][O:25][CH2:24][CH2:23]4)[C:13]4[S:18][C:17]([C:19]([N:28]5[CH2:33][CH2:32][O:31][CH2:30][CH2:29]5)=[O:21])=[CH:16][C:14]=4[N:15]=3)[CH:6]=[CH:7][CH:8]=2)[CH:3]=[N:2]1

Participants

3

Reactant 2

HCID 8083MorpholineHCID 595931412-(1H-Indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidine-6-carboxylic acid

Product 1

HCID 59592972HCID 59592972, compound

Procedure

2-(1H-Indazol-4-yl)-4-morpholinothieno[3,2-d]pyrimidine-6-carboxylic acid 13 (30 mg) was coupled to morpholine via General Procedure B. The product was purified via reverse phase HPLC to give 8.7 mg of 252. MS (Q1) 450.8 (M)+.

Workup

  1. customThe product was purified via reverse phase HPLC

Sources & evidence

ORD record
ord-ccae54baaf564524bfac8d521bb5b297
Source dataset
uspto-grants-2010_12
Patent number
US07846929B2

Reaction notes

Loading…